Track topics on Twitter Track topics that are important to you
Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.
Dr Southan joined Metrion as Head of Commercial Operations in October 2016, was promoted to Chief Operating Officer in April 2017, and joined the board as a director in March 2018. During this period the Company has made significant progress, developing innovative, high-quality assays for its clients and expanding the international customer base into new territories.
Andy has over 25 years of experience in ion channel research and development, starting his career at Wyeth Research (UK), followed by postdoctoral studies at Imperial College London. He has also held leadership roles at CeNeS Pharmaceuticals and Ionix Pharmaceuticals, and spent 12 years leading and expanding the UK ion channel team for BioFocus and Charles River Laboratories.
Keith McCullagh. Chairman of Metrion Biosciences, commented: “Andy has been a driving force supporting Metrion’s growth and success over the past three years. His extensive pharmaceutical CRO industry experience, deep technical understanding of the ion channel field and strong management skills made him the ideal candidate for this new leadership role. I congratulate Andy on his appointment and look forward to working with him to achieve continued progress.”
Dr Andrew Southan, Chief Executive Officer, Metrion Biosciences, said: “It is a pleasure to work with Metrion’s team of expert ion channel specialists, management team and board of directors, and I am looking forward to this next chapter as CEO, further expanding Metrion’s ion channel services as well as the Company’s reputation as a global leader in ion channel biology.”
Photo: Dr Andrew Southan, Chief Executive Officer, Metrion Biosciences
For a high resolution image please contact Zyme Communications
Tel: +44 (0)7787 502 947
Keith McCullagh PhD
Chairman, Metrion Biosciences
About Metrion Biosciences
Metrion Biosciences is a specialist ion-channel contract research organisation and drug discovery business. The Company provides customers with access to a range of high quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences’ specialist ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimisation. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages. For more information, see: www.metrionbiosciences.comNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...